Avidity Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET and the Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET.

Investors and interested parties can access live webcasts and archived replays of both events through the 'Events and Presentations' page in the 'Investors' section of Avidity's website. This participation in major healthcare conferences demonstrates Avidity's commitment to engaging with investors and showcasing its progress in developing innovative RNA therapeutics.

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:

• Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET
• Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET

A live webcast of both events, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302230787.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences (RNA) presenting at the Wells Fargo 2024 Healthcare Conference?

Avidity Biosciences (RNA) is presenting at the Wells Fargo 2024 Healthcare Conference on September 4, 2024, at 5:00 a.m. PT / 8:00 a.m. ET.

What time is Avidity Biosciences (RNA) speaking at the Cantor Global Healthcare Conference?

Avidity Biosciences (RNA) is speaking at the Cantor Global Healthcare Conference on September 17, 2024, at 6:45 a.m. PT / 9:45 a.m. ET.

How can investors access Avidity Biosciences' (RNA) conference presentations?

Investors can access live webcasts and archived replays of Avidity Biosciences' (RNA) conference presentations through the 'Events and Presentations' page in the 'Investors' section of the company's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

What type of RNA therapeutics is Avidity Biosciences (RNA) developing?

Avidity Biosciences (RNA) is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).